Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

The Trump administration and Pfizer PFE announced an agreement on Sept. 30 that includes most-favored-nation pricing for Pfizer’s drugs in Medicaid programs, discounts for direct sales of Pfizer drugs ...

Pfizer's (NYSE:PFE) entry into the obesity treatment market through its $4.9B deal to acquire Metsera (NASDAQ:MTSR) is the latest indication that Big Pharma wants a piece of the weight loss drugs pie ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named the 15 new drugs targeted for Medicare ...

Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major ...

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

President Trump, during an Oval Office event Tuesday, called out Albert Bourla, the CEO of Pfizer, for overcharging Americans for prescription drugs. "The United States has just 4% of the world’s ...